caldaret and Ventricular-Dysfunction--Left

caldaret has been researched along with Ventricular-Dysfunction--Left* in 1 studies

Trials

1 trial(s) available for caldaret and Ventricular-Dysfunction--Left

Article	Year
Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. The American journal of cardiology, 2009, Jan-01, Volume: 103, Issue:1 Primary percutaneous coronary intervention (PCI) decreases myocardial damage in patients with ST-elevation myocardial infarction (STEMI). Cellular reperfusion injury associated with calcium overload may limit myocardial salvage. We previously showed (CASTEMI trial) that caldaret (MCC-135), which modulates myocardial calcium handling when administered before PCI in patients with STEMI, did not change residual left ventricular (LV) function. The aim of this subanalysis was to examine whether caldaret decreases the incidence of LV dysfunction (LV ejection fraction Topics: Angioplasty, Balloon, Coronary; Benzenesulfonates; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Piperazines; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ventricular Dysfunction, Left	2009

Article

Year

Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention.

The American journal of cardiology, 2009, Jan-01, Volume: 103, Issue:1

Primary percutaneous coronary intervention (PCI) decreases myocardial damage in patients with ST-elevation myocardial infarction (STEMI). Cellular reperfusion injury associated with calcium overload may limit myocardial salvage. We previously showed (CASTEMI trial) that caldaret (MCC-135), which modulates myocardial calcium handling when administered before PCI in patients with STEMI, did not change residual left ventricular (LV) function. The aim of this subanalysis was to examine whether caldaret decreases the incidence of LV dysfunction (LV ejection fraction

Topics: Angioplasty, Balloon, Coronary; Benzenesulfonates; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Piperazines; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ventricular Dysfunction, Left

2009